At present, T-DM1 is the only recommended HER2-targeted inhibitor for HER2-mutated NSCLC patients by National Comprehensive Cancer Network (NCCN) Guidelines, with an overall response rate (ORR) of 44% (10). Here, ERBB2 is linked to non-small cell lung carcinoma.